TRICARE Prior Authorization Request Form for semaglutide injection **(Wegovy),** tirzepatide injection (**Zepbound Pen Injector**)

6311

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) TRICARE pharmacy program (TPHARM). Express Scripts is the TPHARM contractor for DoD.

PLEASE NOTE: For Active Duty Service Members, even if coverage will NOT BE APPROVED per this form, it still must be initially submitted to the TPharm Contractor for review. Subsequent reconsideration is allowed at the appropriate Military Treatment Facility. Providers must continue to follow Military Department-specific policies that set the requirements for participation in weight loss programs for Active-Duty Service Members.

For initial review by the TPharm Contractor;
- The provider may **call**: **1-866-684-4488**
or the completed form may be **faxed** to:
1-866-684-4477

- The patient may attach the completed form
to the prescription and **mail** it to: **Express Scripts, P.O. Box 52150, Phoenix, AZ 85072-9954**
or **email** the form only to:
TPharmPA@express-scripts.com

Initial therapy approves for 12 months; annual renewal is required. For renewal of therapy an initial Tricare prior authorization approval is required. Note: Non-FDA approved uses are not approved including diabetes mellitus.

Step 1

Please complete patient and physician information (please print):

Patient Name: _____ Physician Name: _____
Address: _____ Address: _____
_____ _____
Sponsor ID # _____ Phone #: _____
Date of Birth: Secure Fax #:

Step 2

Please complete the clinical assessment:

1. Has the patient received this medication under the TRICARE benefit in the last 6 months? *Please choose "No" if the patient did not previously have a TRICARE approved PA for the requested medication.*	☐ Yes (subject to verification) Proceed to question **22**	☐ No Proceed to question **2**
2. What is the indication or diagnosis?	☐ Obesity - Proceed to question **3** ☐ Moderate to severe obstructive sleep apnea (OSA) in adults with obesity - Proceed to question **15** ☐ Other diagnosis - **STOP - Coverage not approved**	
3. How old is the patient?	☐ Less than 12 years of age - **STOP - Coverage not approved** ☐ Greater than or equal to 12 years of age and less than 18 years of age - Proceed to question **4** ☐ 18 years of age or older - Proceed to question **7**	
4. What is the requested medication?	☐ Wegovy Proceed to question **5**	☐ Zepbound Pen Injector **STOP** **Coverage not approved**
5. Does the patient have a BMI GREATER THAN OR EQUAL TO the 95th percentile standardized for age?	☐ Yes Proceed to question **6**	☐ No **STOP** **Coverage not approved**

6. Has the patient engaged in behavioral modification and dietary restriction for at least 6 months and has failed to achieve the desired weight loss, and will remain engaged throughout course of therapy?	☐ Yes Proceed to question **19**	☐ No **STOP** **Coverage not approved**
7. Does the patient have at least one weight-related comorbidity?	☐ Diabetes or impaired glucose tolerance – Proceed to question **8** ☐ Dyslipidemia – Proceed to question **8** ☐ Hypertension – Proceed to question **8** ☐ Sleep apnea – Proceed to question **8** ☐ Metabolic dysfunction-associated steatohepatitis (MASH) – Proceed to question **8** ☐ Other or NO weight-related comorbidity – Proceed to question **8**	
8. What is the patient's body mass index (BMI)?	☐ Less Than 27 – **STOP - Coverage not approved** ☐ 27 to 29 and a comorbidity is checked above - Proceed to question **9** ☐ 30 to 34 - Proceed to question **10** ☐ 35 to 39 – Proceed to question **10** ☐ Greater than 40 - Proceed to question **10**	
9. Does the patient have at least one weight-related comorbidity (dyslipidemia, hypertension, sleep apnea, MASH)?	☐ Yes Proceed to question **10**	☐ No **STOP** **Coverage not approved**
10. Has the patient engaged in behavioral modification and dietary restriction for at least 6 months and has failed to achieve the desired weight loss, and will remain engaged throughout course of therapy?	☐ Yes Proceed to question **11**	☐ No **STOP** **Coverage not approved**
11. Has the patient tried 3 months of generic phentermine, benzphetamine, diethylpropion (IR/SR) or phendimetrazine IR/SR and failed to achieve a 5% reduction in baseline weight?	☐ Yes Proceed to question **12**	☐ No Proceed to question **13**
12. Please provide drug name, the date and duration of therapy. **Phentermine, benzphetamine, diethylpropion (IR/SR), or phendimetrazine (IR/SR).** **Drug name**_____ **Date**_____ **Duration of therapy** _____ Proceed to question **19**		
13. Does the patient have a contraindication to generic phentermine, benzphetamine, diethylpropion (IR/SR) or phendimetrazine IR/SR (for example, arrhythmias, coronary artery disease, heart failure, stroke, uncontrolled hypertension, etc.)?	☐ Yes Proceed to question **19**	☐ No Proceed to question **14**

14. Has the patient experienced an adverse reaction to phentermine, benzphetamine, diethylpropion (IR/SR) or phendimetrazine IR/SR that is not expected to occur with the requested medication?	☐ Yes Proceed to question **19**	☐ No **STOP** **Coverage not approved**
15. Is the patient 18 years of age or older?	☐ Yes Proceed to question **16**	☐ No **STOP** **Coverage not approved**
16. Does the patient have moderate to severe OSA (documented apnea-hypopnea index GREATER THAN OR EQUAL TO 15 events per hour)?	☐ Yes Proceed to question **17**	☐ No **STOP** **Coverage not approved**
17. Does the patient have a BMI greater than or equal to 30?	☐ Yes Proceed to question **18**	☐ No **STOP** **Coverage not approved**
18. Has the patient engaged in behavioral modification and dietary restriction for at least 6 months?	☐ Yes Proceed to question **19**	☐ No **STOP** **Coverage not approved**
19. Is the patient pregnant?	☐ Yes **STOP** **Coverage not approved**	☐ No **Proceed to question 20**
20. Will the requested medication be used with another GLP1RA (for example, Bydureon, Trulicity, Byetta, Adlyxin, Victoza, Soliqua, Xultophy)?	☐ Yes **STOP** **Coverage not approved**	☐ No Proceed to question **21**
21. Does the patient have a history of or family history of medullary thyroid cancer, or multiple endocrine neoplasia syndrome type 2?	☐ Yes **STOP** **Coverage not approved**	☐ No **Sign and date below**
22. What is the indication or diagnosis?	☐ Obesity - Proceed to question **23** ☐ Moderate to severe obstructive sleep apnea (OSA) in adults with obesity - Proceed to question **29** ☐ Other diagnosis - **STOP - Coverage not approved**	
23. Is the patient currently engaged in behavioral modification and on a reduced calorie diet?	☐ Yes Proceed to question **24**	☐ No **STOP** **Coverage not approved**
24. How old is the patient?	☐ Less than 12 years of age - **STOP Coverage not approved** ☐ Greater than or equal to 12 years of age and less than 18 years of age - Proceed to question **25** ☐ 18 years of age or older - Proceed to question **27**	
25. What is the requested medication?	☐ Wegovy Proceed to question **26**	☐ Zepbound Pen Injector **STOP** **Coverage not approved**

26. Has the patient lost GREATER THAN or EQUAL to 4 percent of baseline body weight since starting medication with full dosage titration?	☐ Yes **Sign and date below**	☐ No **STOP** **Coverage not approved**
27. What is the patient's current body mass index (BMI)?	☐ Less Than 27 – Proceed to question **28** ☐ 27 to 29 - Proceed to question **28** ☐ 30 to 34 - Proceed to question **28** ☐ 35 to 39 – Proceed to question **28** ☐ Greater than 40 - Proceed to question **28**	
28. Has the patient lost GREATER THAN or EQUAL to 5 percent of baseline body weight since starting medication with full dosage titration?	☐ Yes **Sign and date below**	☐ No **STOP** **Coverage not approved**
29. Has the patient shown improvement in OSA symptoms based on the improvement of apnea hypopnea index?	☐ Yes **Sign and date below**	☐ No **STOP** **Coverage not approved**

Step 3 **I certify the above is true to the best of my knowledge.** Please sign and date:

Prescriber Signature _____ Date _____